Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 4,760 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Branch II Clear all
Completed Phase 2Phase 3 Interventional

Celecoxib in Treating Patients With Bladder Cancer

NCT00006124
View directory record Official record
Conditions
Recurrent Bladder Cancer
Interventions
celecoxib, placebo
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer

NCT00450723
View directory record Official record
Conditions
Breast Cancer
Interventions
Isosulfan blue, Axillary Lymph Node Dissection, Surgery, Sentinel Lymph Node Biopsy, Thoracoscopic Surgery, Technetium Tc 99m Sulfur Colloid
Drug · Procedure · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 31, 2026, 10:22 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

NCT05470491
View directory record Official record
Conditions
HIV, Hematologic Malignancies
Interventions
RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

NCT01708174
View directory record Official record
Conditions
Medulloblastoma
Interventions
LDE225, TMZ
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
4 Months and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 31, 2026, 10:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

NCT04708418
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Recurrent Cutaneous Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography, Surgical Procedure, VLP-encapsulated TLR9 Agonist CMP-001
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
187
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 134 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors

NCT03372720
View directory record Official record
Conditions
Cervical Carcinoma, Dyspareunia, Endometrial Carcinoma, Ovarian Carcinoma, Vaginal Carcinoma, Vaginal Dryness, Vulvar Carcinoma
Interventions
Laser Therapy, Questionnaire Administration, Sham Intervention
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Fargo, North Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

NCT00661609
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Bladder Cancer, Urethra Cancer, Ureter Cancer, Renal Pelvis Cancer
Interventions
AZD4877
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Palo Alto, California • San Bernardino, California • Southington, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2011 · Synced Oct 31, 2026, 10:22 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

GARM II: A Study on the Genetics of Age-related Maculopathy

NCT01115387
View directory record Official record
Conditions
Age-related Macular Degeneration, Age-related Maculopathy
Interventions
Observational-1, Observational-2
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
49 Years and older
Enrollment
603 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

NCT01959139
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
154
States / cities
Anchorage, Alaska • Tucson, Arizona • Auburn, California + 112 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Not applicable Interventional

TMS for the Treatment of Pancreatic Cancer Pain

NCT00324428
View directory record Official record
Conditions
Pain, Visceral Pain, Pancreatic Cancer
Interventions
Transcranial Magnetic Stimulation
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Results available

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

NCT04147234
View directory record Official record
Conditions
Neoplasms
Interventions
BI 1387446 50 μg, BI 754091, BI 1387446 100 μg, BI 1387446 200 μg, BI 1387446 400 μg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 31, 2026, 10:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

NCT04954001
View directory record Official record
Conditions
Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Interventions
FCN-159
Drug
Lead sponsor
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Industry
Eligibility
2 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • St. Petersburg, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Healthy Caregivers-Healthy Children (HC2) Phase II

NCT02697565
View directory record Official record
Conditions
Pediatric Obesity, Obesity
Interventions
Healthy Caregivers- Healthy Children Toolkit, Safety Curriculum
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
2 Years to 5 Years
Enrollment
2,289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 31, 2026, 10:22 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users

NCT06909500
View directory record Official record
Conditions
Nicotine Dependence, Tobacco-Related Carcinoma
Interventions
Smartphone app, Text Message, Survey Administration
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 30 Years
Enrollment
1,178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 31, 2026, 10:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

NCT00555399
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Glioma
Interventions
Vorinostat, Isotretinoin, Surgical Resection, Temozolomide
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

NCT02701400
View directory record Official record
Conditions
Recurrent Small Cell Lung Carcinoma
Interventions
Durvalumab, Hypofractionated Radiation Therapy, Stereotactic Body Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Warm Ischemia or Cold Ischemia During Surgery in Treating Patients With Stage I Kidney Cancer

NCT00743236
View directory record Official record
Conditions
Kidney Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Perioperative/Postoperative Complications, Urinary Complications
Interventions
cold ischemia procedure, warm ischemia procedure
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Orange, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Early Phase 1 Interventional

Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

NCT03238365
View directory record Official record
Conditions
Lip, Oral Cavity and Pharynx, Larynx
Interventions
Nivolumab, Tadalafil, Therapeutic Conventional Surgery
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

NCT00055809
View directory record Official record
Conditions
Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor
Interventions
PEG-interferon alfa-2b, bevacizumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis

NCT04245709
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Clenbuterol
Drug
Lead sponsor
Dwight Koeberl, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 31, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

NCT05361798
View directory record Official record
Conditions
Cancer Of Prostate
Interventions
PDS01ADC, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

NCT02471430
View directory record Official record
Conditions
HIV Infection
Interventions
Panobinostat, Pegylated Interferon-alpha2a
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 31, 2026, 10:22 AM EDT
Withdrawn Phase 2 Interventional

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

NCT03035630
View directory record Official record
Conditions
Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
Interventions
Avelumab, Sunitinib
Drug
Lead sponsor
Guru Sonpavde
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 31, 2026, 10:22 AM EDT
Withdrawn Phase 2 Interventional

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

NCT04351230
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Abemaciclib, Trastuzumab Emtansine
Drug · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Yuma, Arizona • Jacksonville, Florida • Urbana, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 31, 2026, 10:22 AM EDT